HTML
-
The transmission route of COVID-19 is shown in Supplementary Figure S1. The baseline characteristics of recovered patients with COVID-19 are shown in Table 1. Fifty-six patients diagnosed with common type COVID-19 in the three designated tertiary hospitals in Jilin Province were included in the study. The median age was 40 years, ranging from 10 to 87 years old (interquartile range, 28-52), and 26.8% (15/56) were older than 50 years. A total of 44.6% (25/56) of the patients were female. At the final date of research, all 56 patients had been discharged. The average length of hospital stay was 17 days (interquartile range, 11-20). In total, 12.5% (7/56) of the patients had a history of traveling to Wuhan, and 30.4% (17/56) had a history of traveling outside Wuhan. A total of 42.9% (24/56) were primary cases, who had not left Jilin Province recently but had a history of close exposure to imported cases, and 14.2 (8/56) were secondary cases, who had a history of close exposure primary cases.
Male (n = 31) Female (n = 25) Hospitalized time, d, M (P25-P75) 17 (14-21) 18 (11-20) Age, y, M (P25-P75) 40 (29-50) 41 (28-53) Travel history in Wuhan 5 (16.1) 2 (8.0) City Changchun 22 (71.0) 20 (80.0) Siping 9 (29.0) 5 (20.0) Age groups < 30 y 10 (32.2) 8 (32.0) 30-49 y 13 (41.9) 10 (40.0) 50-69 y 6 (19.4) 5 (20.0) ≥ 70 y 2 (6.5) 2 (8.0) Contact category Imported cases 15 (48.4) 9 (36.0) Primary cases 10 (32.2) 14 (56.0) Secondary cases 6 (19.4) 2 (8.0) Data are n (%) unless specified otherwise
y: year; d: dayTable 1. The baseline characteristics of recovered cases with COVID-19.
-
The laboratory findings of patients with COVID-19 from onset to hospital admission are shown in Table 2. Regarding leukocyte parameters, white blood cell (WBC), neutrophil (NE), lymphocyte (LY), and eosinophil (EO) counts below the lower limit of the RIs were observed in 14.3%-50.0% of patients, while both the basophil (BA) and monocyte (MO) counts beyond the upper limit of the RI were observed in 5.4% and 7.1% of patients, respectively. In terms of erythrocyte parameters, decreased red blood cell (RBC) counts, the levels of hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) were observed in 3.6%-12.5% of patients. Regarding platelet parameters, platelet count (PLT) and thrombocytocrit (PCT) values below the lower limit of the RI were observed in 12.5% and 5.4% of the patients, respectively. In terms of coagulation parameters, the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), and international normalized ratio (INR) above the upper limit of the RI were found in 8.6%-25.7% cases, while fibrinogen (FBG) levels below the lower limit of the RI were found in 17.1% cases. The concentration of high-sensitivity C-reactive protein (hsCRP) was higher than the upper limit of the RI in 48.8% of cases. Regarding serum cardiac markers, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK), creatinine kinase-muscle/brain activity (CK-MB), and cardiac troponin I (cTnI) values beyond the upper limit of the RI were observed in 6.4%-41.4% of the patients. In the liver function tests, alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), total bilirubin (TBIL), and direct bilirubin (DBIL) values above the upper limit of RI were found in 2.1%-23.4% of the patients, while cholinesterase (CHE), total protein (TP), albumin (ALB), globulin (GLB), and indirect bilirubin values below the lower limit of the RI were observed in 0.0%-57.4% of the patients. In kidney function tests, blood urea nitrogen (BUN) and creatinine (Cr) values above the upper limit of the RI were found in 2.1% and 4.3% of the patients, respectively. In electrolyte tests, potassium (K), sodium (Na) and chloride (Ca) values below the lower limit of the RI were observed in 4.2%-41.7% of the patients, respectively.
Analytes Reference intervals Median (P25-P75) Increase (n%) Decrease (n%) Male Female Leukocyte parameters WBC, ×109/L 3.50-9.50 5.24 (3.98-6.30) 1/56 (1.8) 8/56 (14.3) NE, ×109/L 1.80-6.30 3.40 (2.58-4.38) 3/56 (5.4) 9/56 (16.1) LY, ×109/L 1.10-3.20 1.20 (0.90-1.66) 1/56 (1.8) 21/56 (37.5) EO, ×109/L 0.02-0.52 0.02 (0.00-0.04) 0/56 (0.0) 28/56 (50.0) BA, ×109/L 0.00-0.06 0.02 (0.00-0.03) 3/56 (5.4) 0/56 (0.0) MO, ×109/L 0.10-0.60 0.31 (0.25-0.50) 4/56 (7.1) 0/56 (0.0) Erythrocyte parameters RBC, ×1012/L 4.30-5.80 3.80-5.10 4.69 (4.29-5.09) 2/56 (3.6) 6/56 (10.7) HGB, g/L 130-175 115-150 145 (133-158) 2/56 (3.6) 2/56 (3.6) HCT, L/L 0.400-0.500 0.350-0.450 0.420 (0.386-0.446) 1/56 (1.8) 7/56 (12.5) MCV, fL 82.0-100.0 89.6 (86.6-92.3) 3/56 (5.4) 2/56 (3.6) MCH, pg 27.0-34.0 31.0 (30.0-31.9) 4/56 (7.1) 2/56 (3.6) MCHC, g/L 316-354 345 (341-349) 3/56 (5.4) 0/56 (0.0) RDW, % 11.00-16.00 11.60 (11.28-11.90) 0/56 (0.0) 6/56 (10.7) Platelet parameters PLT, ×109/L 125-350 202 (164-231) 4/56 (7.1) 7/56 (12.5) MPV, fL 6.5-12.0 9.4 (8.6-10.0) 0/56 (0.0) 0/56 (0.0) PDW, % 9.0-17.0 12.5 (10.9-14.2) 4/56 (7.1) 0/56 (0.0) PCT, % 0.108-0.282 0.180 (0.149-0.199) 5/56 (8.9) 3/56 (5.4) Coagulation parameters TT, s 14.0-20.0 15.6 (15.0-16.2) 0/35 (0.0) 0/35 (0.0) APTT, s 22.2-38.0 34.7(31.9-36.2) 4/35 (11.4) 0/35 (0.0) PT, s 11.0-13.0 11.9 (11.6-13.0) 9/35 (25.7) 2/35 (5.7) INR 0.90-1.30 1.07 (1.00-1.16) 3/35 (8.6) 1/35 (2.9) FBG, g/L 2.00-4.00 2.20 (2.01-3.13) 5/35 (14.3) 6/35 (17.1) Cardiac markers parameters hsCRP, mg/L < 6.0 6.0 (2.4-22.6) 21/43 (48.8) - Mb, ng/ml 0.0-61.5 22.7 (19.4-26.0) 0/30 (0.0) 0/30 (0.0) cTnI, ng/ml < 1.50 1.30 (1.10-1.80) 12/29 (41.4) - CK, U/L 50-310 40-200 76 (55-114) 3/47 (6.4) 5/47 (10.6) CK-MB, U/L 0.0-24.0 15.0 (11.5-22.0) 10/47 (21.3) 0/47 (0.0) LDH, L 120-250 207 (184-258) 13/47 (27.7) 0/47 (0.0) AST, U/L 15.0-40.0 13.0-35.0 25.0 (20.0-29.5) 6/47 (12.8) 1/47 (2.1) Liver function parameters ALT, U/L 9.0-50.0 7.0-40.0 25.0 (19.0-44.0) 11/47 (23.4) 0/47 (0.0) GGT, U/L 10.0-60.0 7.0-45.0 23.5 (15.0-39.5) 8/46 (17.4) 0/46 (0.0) CHE, U/L 5000-12000 8426 (6981-9023) 0/39 (0.0) 0/39 (0.0) TP, g/L 65.0-85.0 67.8 (65.3-71.7) 0/47 (0.0) 10/47 (21.3) ALB, g/L 40.0-55.0 44.1 (42.2-45.7) 0/47 (0.0) 4/47 (8.5) GLB, g/L 20.0-40.0 23.7 (21.7-26.7) 0/47 (0.0) 7/47 (14.9) TBIL, pmol/L < 23.0 7.9 (6.8-12.8) 1/47 (2.1) - DBIL, pmol/L < 8.0 3.6 (3.2-5.1) 1/47(2.1) - IBIL, pmol/L 5.10-21.40 4.40 (3.45-7.00) 0/47 (0.0) 27/47 (57.4) Kidney function parameters BUN, mmol/L 3.10-8.00 2.60-7.50 3.69 (3.08-4.70) 1/47 (2.1) 9/47 (19.1) Cr, pmol/L 57.0-97.0 41.0-73.0 68.0 (58.8-76.7) 2/47 (4.3) 2/47 (4.3) CO2-CP, mmol/L 22.0-29.0 20.7 (18.9-22.4) 0/47 (0.0) 32/47 (68.1) Glu, mol/L 3.89-6.11 6.04 (5.54-6.69) 23/47 (48.9) 0/47 (0.0) Electrolyte parameters K, mmol/L 3.50-5.30 4.08 (3.89-4.37) 1/48 (2.1) 2/48 (4.2) Na, mmol/L 137-147 138 (137-140) 0/48 (0.0) 12/48 (25.0) Cl, mmol/L 99-110 100 (98-102) 0/48 (0.0) 20/48 (41.7) WBC, White blood cell; NE, Neutrophil; LY, Lymphocyte; EO, Eosinophil; BA, Basophil; MO, Monocyte; RBC, Red blood cell; HGB, Hemoglobin; HCT, Hematocrit; MCV, Mean corpuscular volume; MCH, Mean corpuscular hemoglobin; MCHC, Mean corpuscular hemoglobin concentration; RDW, Red blood cell distribution width; PLT, Platelet count; MPV, Mean platelet volume; PDW, Platelet distribution width; PCT, Thrombocytocrit; TT, Thrombin time; APTT, Activated partial thromboplastin time; PT, Prothrombin time; INR, International normalized ratio; FBG, Fibrinogen; hsCRP, High-sensitivity C-reactive protein; Mb, Myoglobin; cTnI, Cardiac Troponin I; CK, Creatine kinase; CK-MB, Creatinine kinase-muscle/brain activity; LDH, Lactate dehydrogenase; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; GGT, γ-glutamyl transpeptidase; CHE, Cholinesterase; TP, Total protein; ALB, Albumin; GLB, Globulin; TBIL, Total bilirubin; DBIL, Direct bilirubin; IBIL, Indirect bilirubin; BUN, Blood urea nitrogen; Cr, Creatinine; CO2-CP, Carbon dioxide combining power; Glu, Glucose; K, Potassium; Na, Sodium; Cl, Chloride Table 2. Laboratory findings of patients with COVID-19 at onset to hospital admission.
-
The trajectories of the laboratory tests over time are shown in Fig. 1. The average value of EO was near the lower limit of the RI at onset, and while it continued to significantly increase, the value was always below the upper limit of the RI until discharge. The average value of NE gradually increased from onset, peaking on day 12, and then steadily fell to the lower limit of the RI. The average value of LY approached the lower limit of the RI for the first 5 days and then rose slowly thereafter, reaching a peak around day 20. The NE/LY ratio peaked on day 5 and slowly declined thereafter. The average values of MO and BA showed U-shaped trends, peaking on day 17. The platelet parameters—PLT, PCT and mean platelet volume (MPV)—were within the RI in all cases. The average value of PCT peaked on day 7 and slowly declined thereafter, while the average value of MPV decreased sharply after day 7 and even approached to the lower limit of the RI. There was no significant change in erythrocyte parameters, including RBC, HGB, HCT, MCH, and MCHC. However, the average value of MCV showed an upward trend from day 8. The average value of cTnI sharply declined, and the average carbon dioxide combining power significantly increased throughout the course of the disease. Interestingly, the average value of serum sodium showed an upward trend after day 15. The other hematological and biochemical tests results were not shown a significant trend over time.
Figure 1. Temporal trajectories of laboratory parameters. A Neutrophil. B Lymphocyte. C Neutrophil/Lymphocyte. D Eosinophil. E Basophil. F Monocyte. G Mean corpuscular volume. H Platelet count. I Thrombocytocrit. J Mean platelet volume. K Hematocrit. L Cardiac Troponin I. M Lactate dehydrogenase. N Globulin. O Carbon dioxide combining power. P Sodium. Here, only the representative parameters over time are presented. The gray dotted line represents the upper limit of the RI, whereas the purple dotted line represents the lower limit.
-
The test results during the early period of hospitalization (< 5 days) are summarized as their respective means, which were used in the analysis hereafter. Cox regression models indicated that PCT, PLT, MO, LDH and GLB were predictors (P = 0.071, P = 0.041, P = 0.052, P = 0.023, P = 0.064, respectively). The correlation plot of these 5 variables, age and sex were presented in Fig. 2A. As expected, PCT and PLT were highly positively correlated with each other. Then the refined feature selection step was carried out with these 5 variables, age and sex as candidate markers. While LASSO selected LDH and GLB, backwards selection chose none of the variables, and stepwise selection chose LDH and PLT as predictors. Given that a certain feature selection method has its own advantages and disadvantages, the final model includes these three parameters in addition to age and sex which are clinically significant, as shown as the chosen predictors (Patil et al. 2020; Tadiri et al. 2020). The AUCs of these variables for predicting recovery at days 7, 14 and 21 with the LASSO, stepwise selection methods, and the final model are presented in Fig. 2B. Overall, the final model performed the best, justifying its superiority. As shown by the nomogram of this final model (Fig. 3), when PLT (P = 0.05), LDH (P = 0.03) and GLB (P = 0.58) levels in the early period were low, the chance of a quick recovery tended to decrease, whereas for a younger patient (P = 0.43) and a female patient (P = 0.33) the probability of quick recovery tended to be higher. Nevertheless, all parameters except LDH were not significant predictors.
Figure 2. Feature selection process for relevant laboratory parameters that have prognostic value for recovery. A Correlation plot of the parameters selected by Cox regression models and age. B Areas under the ROC curves (AUCs) of three feature selection models for predicting recovery at days 7, 14 and 21. The final model including age, sex, lactate dehydrogenase (LDH), platelet count (PLT) and globulin (GLB) was used.
-
Twenty-four common type patients with COVID-19 were included in the validation set. For these patients, age ranged from 4 to 70, the ratio of male to female was 1.14:1 and the duration of hospitalization was 8-67 days.
Using the final model obtained from the training set (the previous cohort including patients from Changchun and Siping areas), as given in the nomogram plot, the risk scores of not recovery for the patients in the validation set were calculated and then the C-index statistics were obtained. As shown in Fig. 4, the corresponding C-indices are 0.825, 0.852, and 0.604 at the end points of day 8, day 14, and day 21, respectively (of note, since the shortest stay for the validation set is day 8, the C-index with day 7 cannot be computed).